Acutaas Chemicals cash flow

Latest FY26

Cash from operations: ₹292cr+146.9% on FY25
Capital spending: ₹328cr+68.5% on FY25
Free cash flow: −₹35.8cr−₹76.3 cr in FY25
Cash from financing: ₹4.1cr−98.4% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	36.0	26.6	16.1	13.1
	—	3.1	6.2	5.9	2.4
	—	−8.5	−10.8	−2.2	−2.2
	—	0.0	−0.0	0.0	−0.0
	—	0.0	0.0	2.3	0.0
	—	−16.0	−6.1	−4.2	0.8
	—	2.6	3.0	0.3	0.0
	—	−0.0	0.0	0.0	0.0
	—	−3.0	0.0	0.0	0.0
	—	−51.4	−23.2	−35.1	−7.0
	—	−55.5	−80.1	30.0	−64.4
	—	−3.7	−3.0	1.0	4.6
	—	0.0	0.0	31.8	0.0
	—	10.2	5.2	−28.4	−0.9
	—	0.0	0.0	−0.2	0.4
	—	−2.1	21.4	23.6	23.6
	—	1.0	−2.8	24.9	1.8
	—	8.4	12.4	1.9	5.6
Cash from operating activities
	600	483	216	81.9	112
	—	−79.0	−51.1	67.6	−22.2
	—	404	165	150	90.0
	—	112	46.7	24.3	24.5
	—	292	118	125	65.5
Cash from investing activities
	—	328	195	280	96.4
	—	0.0	0.0	66.0	0.0
	—	0.0	0.0	34.3	−61.2
	—	0.9	0.0	0.0	0.0
	—	0.0	0.0	13.0	0.0
	—	0.0	0.0	0.0	0.0
	—	8.5	10.8	2.3	2.2
	—	54.4	−40.1	0.0	0.0
	—	−266	−224	−365	−33.0
Cash from financing activities
	—	0.0	499	51.9	0.0
	—	18.3	0.0	218	2.8
	—	0.0	208	0.0	0.0
	—	0.7	0.3	0.0	0.0
	—	1.3	6.2	5.9	2.4
	—	12.3	12.3	10.9	10.9
	—	0.0	−11.0	−13.7	−1.7
	—	4.1	261	239	−12.3
	—	30.3	156	−0.9	20.2
	—	0.0	0.0	0.0	0.0
	—	30.3	156	−0.8	20.2
	—	—	185	29.7	30.5
Reference items
	623	480	232	128	123
	39.1%	35.9%	23.1%	17.9%	19.9%
	−35.8	−35.8	−76.3	−155	−30.9
	—	−18.8	−291	51.9	—
	−₹4.37	−₹4.37	−₹9.32	−₹18.95	−₹3.77
	—	0.82×	0.74×	2.57×	0.79×
	—	112	46.7	24.3	24.5
	—	1.3	6.2	5.9	2.4

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ACUTAAS₹3,976.70

Acutaas Chemicals Ltd.

· Pharma & Health

₹ CrorePeersANURAS AETHER BLUEJET CAPLIPOINT CONCORDBIO EMCURE JBCHEPHARM ERISMcap ₹32,558 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	13.1	16.1	26.6	36.0	—
+ Finance Costs	2.4	5.9	6.2	3.1	—
+ Interest Income	-2.2	-2.2	-10.8	-8.5	—
+ Dividend Income	-0.0	0.0	-0.0	0.0	—
+ Share-based Payments	0.0	2.3	0.0	0.0	—
+ Unrealised FX (Gain) / Loss	0.8	-4.2	-6.1	-16.0	—
+ Other Non-cash Items	0.0	0.3	3.0	2.6	—
+ Other — Cash Effects are Investing / Financing	0.0	0.0	0.0	-0.0	—
+ Other Reconciling Items	0.0	0.0	0.0	-3.0	—
Changes in Working Capital
+ Inventories	-7.0	-35.1	-23.2	-51.4	—
+ Trade Receivables — Current	-64.4	30.0	-80.1	-55.5	—
+ Other Financial Assets — Current	4.6	1.0	-3.0	-3.7	—
+ Other Financial Assets — Non-current	0.0	31.8	0.0	0.0	—
+ Other Current Assets	-0.9	-28.4	5.2	10.2	—
+ Other Non-current Assets	0.4	-0.2	0.0	0.0	—
+ Trade Payables — Current	23.6	23.6	21.4	-2.1	—
+ Other Current Liabilities	1.8	24.9	-2.8	1.0	—
+ Provisions — Current	5.6	1.9	12.4	8.4	—
Cash from Operating Activities
Profit Before Tax (per I/S)	112.2	81.9	216.2	482.7	599.7
+ Total Adjustments (incl. Working Capital)	-22.2	67.6	-51.1	-79.0	—
Cash from Operations (pre-tax)	90.0	149.5	165.1	403.7	—
+ Income Taxes Paid	24.5	24.3	46.7	111.6	—
Cash from Operating Activities	65.5	125.2	118.3	292.2	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	96.4	280.4	194.6	328.0	—
+ Acq of Investment Property	0.0	66.0	0.0	0.0	—
+ Acq of Other Long-term Assets	-61.2	34.3	0.0	0.0	—
+ Investment in Partnership Firms / LLPs	0.0	0.0	0.0	0.9	—
+ Loans & Advances Repaid	0.0	13.0	0.0	0.0	—
+ Dividends Received — Investing	0.0	0.0	0.0	0.0	—
+ Interest Received — Investing	2.2	2.3	10.8	8.5	—
+ Other Inflows / (Outflows) — Investing	0.0	0.0	-40.1	54.4	—
Cash from Investing Activities	-33.0	-365.4	-223.9	-265.9	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.0	51.9	499.4	0.0	—
+ Proceeds from Borrowings	2.8	218.1	0.0	18.3	—
+ Repayment of Borrowings	0.0	0.0	208.5	0.0	—
+ Payment of Lease Liabilities	0.0	0.0	0.3	0.7	—
+ Interest Paid	2.4	5.9	6.2	1.3	—
+ Dividends Paid	10.9	10.9	12.3	12.3	—
+ Other Inflows / (Outflows) — Financing	-1.7	-13.7	-11.0	0.0	—
Cash from Financing Activities	-12.3	239.4	261.1	4.1	—
Net Changes in Cash (pre-FX)	20.2	-0.9	155.5	30.3	—
+ Effect of FX Rate Changes on Cash	0.0	0.0	0.0	0.0	—
Net Changes in Cash	20.2	-0.8	155.5	30.3	—
Closing Cash	30.5	29.7	185.2	—	—
Reference Items
EBITDA	122.6	128.5	232.1	480.4	623.2
EBITDA Margin %	19.88	17.91	23.05	35.87	39.13
Free Cash Flow (CFO − Capex)	-30.9	-155.2	-76.3	-35.8	-35.8
Free Cash Flow to Equity	—	51.9	-291.0	-18.8	—
Free Cash Flow per Basic Share	-3.77	-18.95	-9.32	-4.37	-4.37
Cash Flow to Net Income	0.79	2.57	0.74	0.82	—
Cash Paid for Taxes	24.5	24.3	46.7	111.6	—
Cash Paid for Interest	2.4	5.9	6.2	1.3	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.